GSK Reaches up to $690 Million Licensing Agreement With Alfasigma

Paul, Weiss is advising GSK plc on a licensing agreement with Italy-based Alfasigma S.p.A., a global pharmaceutical company with significant experience developing and selling treatments for serious liver diseases. Under the agreement Alfasigma will acquire worldwide exclusive rights to develop, manufacture and commercialize linerixibat, an investigational ileal bile acid transporter inhibitor being developed for cholestatic pruritus in primary biliary cholangitis, a rare chronic autoimmune disease affecting the liver. GSK will receive an upfront payment of $300 million, plus $100 million upon U.S. FDA approval, $20 million upon EU and UK approval, and up to $270 million in sales-based milestone payments. GSK will also earn tiered double-digit royalties on net sales worldwide.

The Paul, Weiss team is led by intellectual property partners Jonathan Ashtor and John Patten, and includes partners Jeffrey Osterman and Brianna van Kan, and counsel Georgina Hoy; and antitrust partner Christopher Wilson.